Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Torres-Guzman, R; Calsina, B; Hermoso, A; Baquero, C; Alvarez, B; Amat, J; McNulty, AM; Gong, XQ; Boehnke, K; Du, J; de Dios, A; Beckmann, RP; Buchanan, S; Lallena, MJ

Lallena, MJ (reprint author), Eli Lilly & Co, Quantitat Biol, Madrid, Spain.

ONCOTARGET, 2017; 8 (41): 69493

Abstract

Abemaciclib is an ATP-competitive, reversible kinase inhibitor selective for CDK4 and CDK6 that has shown antitumor activity as a single agent in horm......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索